Supported by the National Institutes of Health (NIH), Grant number: NCCAM AT003400; and the Children's Medical Center Research Foundation. Partial funding was obtained from Schering-Plough, Canada, which allowed patient recruitment and stool collection. E.W. is an Alberta Innovates Health Solutions (AIHS) Clinical Investigator. Infrastructure in E.W.'s laboratory is funded by the Centre for Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) at the University of Alberta and the Alberta Inflammatory Bowel Disease Consortium, which is supported by an AIHS Interdisciplinary Team Grant.
Alterations in the gut microbiome of children with severe ulcerative colitis†
Article first published online: 14 DEC 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 10, pages 1799–1808, October 2012
How to Cite
Michail, S., Durbin, M., Turner, D., Griffiths, A. M., Mack, D. R., Hyams, J., Leleiko, N., Kenche, H., Stolfi, A. and Wine, E. (2012), Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis, 18: 1799–1808. doi: 10.1002/ibd.22860
- Issue published online: 13 SEP 2012
- Article first published online: 14 DEC 2011
- Manuscript Accepted: 28 NOV 2011
- Manuscript Received: 15 NOV 2011
- ulcerative colitis;
- steroid therapy;
- microbial diversity
Although the role of microbes in disease pathogenesis is well established, data describing the variability of the vast microbiome in children diagnosed with ulcerative colitis (UC) are lacking. This study characterizes the gut microbiome in hospitalized children with severe UC and determines the relationship between microbiota and response to steroid therapy.
Fecal samples were collected from 26 healthy controls and 27 children hospitalized with severe UC as part of a prospective multicenter study. DNA extraction, polymerase chain reaction (PCR) amplification of bacterial 16S rRNA, and microarray hybridization were performed. Results were analyzed in GeneSpring GX 11.0 comparing healthy controls with children with UC, and steroid responsive (n = 17) with nonresponsive patients (n = 10).
Bacterial signal strength and distribution showed differences between UC and healthy controls (adjusted P < 0.05) for Phylum, Class, Order, Family, Genus, and Phylospecies levels with reduction in Clostridia and an increase in Gamma-proteobacteria. The number of microbial phylospecies was reduced in UC (266 ± 69) vs. controls (758 ± 3, P < 0.001), as was the Shannon Diversity Index (6.1 ± 0.23 vs. 6.49 ± 0.04, respectively; P < 0.0001). Steroid nonresponders harbored fewer phylospecies than responders (142 ± 49 vs. 338 ± 62, P = 0.013).
Richness, evenness, and biodiversity of the gut microbiome were remarkably reduced in children with UC compared with healthy controls. Children who did not respond to steroids harbored a microbiome that was even less rich than steroid responders. This study is the first to characterize the gut microbiome in a large cohort of pediatric patients with severe UC and describes changes in the gut microbiome as a potential prognostic feature. (Inflamm Bowel Dis 2012)